MEN1 and pancreatic neuroendocrine tumor: Despite substantial improvement of the overall survival of patients with MEN1, gastroenteropancreatic neuroendocrine tumors, malignant nonfunctioning pancreatic neuroendocrine tumors in particular (25, 28, 29), remain associated with increased morbidity and mortality.